Results 61 to 70 of about 1,275 (182)

CYTOPATHIC EFFECTS OF ACCELERATOR-BASED BORON NEUTRON CAPTURE THERAPY ON HUMAN GLIOBLASTOMA CELLS

Сибирский онкологический журнал, 2019
Boron neutron capture therapy (BNCT) is a targeted therapy based on a selective damage to cancer cells due to the interaction between boron-10 isotope and neutron.
V. A. Byvaltsev, E. L. Zavjalov, V. V. Kanygin, A. I. Kasatova, A. I. Kichigin, I. A. Razumov, T. V. Sycheva, S. Yu. Taskaev   +7 more
doaj   +1 more source

Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma

Advanced Science, EarlyView.
Aptamers have remarkable recognition capacity which is suitable for assisting drug delivery for GB. This review demonstrates that aptamers have great potential as targeted therapeutic carriers, conjugated to various therapeutic carriers, using a range of conjugation strategies and chemistries.
Alexandra R. Paul, Alexandra Moreno Mitchell, Dean O'Neil, Yutong Luo, Khuloud T. Al‐Jamal   +4 more
wiley   +1 more source

Mechanochemical preparation of a water-dispersible fluorescent boron-fused π-conjugated polymer–hyaluronic acid complex as a boron agent for boron neutron capture therapy [PDF]

RSC Mechanochemistry
Boron neutron capture therapy (BNCT) requires boron agents that enable efficient tumor accumulation, intracellular delivery, and precise distribution assessment. Herein, we report a supramolecular strategy to construct a theranostic boron delivery system
Taiki Saito, Riku Kawasaki, Yuto Aoyama, Shunichiro Ito, Kazuo Tanaka, Yamato Miura, Yu Sanada, Minoru Suzuki, Naoki Tsurumori, Koki Matsuda, Takeshi Nagasaki, Risako Miura, Keita Yamana, Atsushi Ikeda   +13 more
doaj   +1 more source

Boron‐embedded multifunctional nanoplatform toward potential combined boron neutron capture therapy and immunomodulation in glioma

Smart Molecules, EarlyView.
A brain‐targeting multifunctional nanoplatform (DM&Ce6@COF‐Ang) was engineered by employing boron‐enriched APTES‐COF‐1 as both the therapeutic boron agent and the nanocarrier co‐delivery of DMXAA and Ce6. This nanoplatform achieved synergistic tumor‐specific boron delivery, real‐time pharmacokinetic monitoring, and immunomodulation.
Yiming Liu, Xuejian Wang, Bangjian Li, Kun Shao, Jianlong Su, Yang Wang, Lin Cheng, Zhihao Wu, JinRong Li, Guanyi Zhang, Xu Wang, Yuxuan Zhang, Yuanhao Liu, Guangzhe Li   +13 more
wiley   +1 more source

Glioma Stem-Like Cells Can Be Targeted in Boron Neutron Capture Therapy with Boronophenylalanine

, 2020
As glioma stem cells are chemo- and radio-resistant, they could be the origins of recurrent malignant glioma. Boron neutron capture therapy (BNCT) is a tumor-selective particle radiation therapy.
Masaki Hikida, Minoru Suzuki, Mitsutoshi Nakada, Eishu Hirata, Satoshi Takeno, Yoshinori Sakurai, Natsuko Kondo   +6 more
core   +1 more source

Improving the bioactivity of rHirudin with boronophenylalanine site-specific modification

Molecular Medicine Reports, 2015
To improve the bioactivity of recombinant (r)Hirudin, the orthogonal pair MjBTyrRS/tRNATyr cua (made up of the boronophenylalanine, tRNA and tRNA synthetase), was selected to incorporate boronophenylalanine site‑specifically into rHirudin at the 63 sites in an Escherichia coli system in response to the TAG codon.
Xiujuan, Xin, Wenshe, Liu, Liyun, Sun
openaire   +3 more sources

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, Volume 13, Issue 52, 18 September 2026.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source

Optimized ¹H MRS and MRSI methods for the in vivo detection of boronophenylalanine [PDF]

Magnetic Resonance in Medicine, 2005
AbstractBoronophenylalanine (BPA) is used as Boron‐10 carrier in boron neutron capture therapy, an experimental cancer radiotherapy. Results of quantitative, noninvasive in vivo detection and imaging of BPA in laboratory animals using 1H NMR are presented for the first time.
Peter, Bendel, Raanan, Margalit, Yoram, Salomon   +2 more
openaire   +2 more sources

Drug Delivery With Metal–Organic Frameworks

Angewandte Chemie Novit, Volume 2, Issue 3, September 2026.
Metal–organic frameworks (MOFs) have recently entered human clinical trials for cancer radiotherapy, highlighting both the maturity and potential of MOFs as platforms for drug delivery. This minireview introduces the principles of MOF‐based drug delivery and discusses key opportunities and design challenges that will shape the next generation of these ...
Nathalie W. Tarabay, Alexander S. Evtushenko, Mohammad Reza Alizadeh Kiapi, Xu Chen, Katia Caamaño, Ljiljana Fruk, David Fairen‐Jimenez   +6 more
wiley   +1 more source

Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients

Clinical and Translational Radiation Oncology, 2022
Purpose: This study reports the first-in-human use of a linear accelerator-based boron neutron capture therapy (BNCT) system and the first treatment of patients with scalp-angiosarcoma with accelerator-based BNCT.
Hiroshi Igaki, Naoya Murakami, Satoshi Nakamura, Naoya Yamazaki, Tairo Kashihara, Akira Takahashi, Kenjiro Namikawa, Mihiro Takemori, Hiroyuki Okamoto, Kotaro Iijima, Takahito Chiba, Hiroki Nakayama, Ayaka Takahashi, Tomoya Kaneda, Kana Takahashi, Koji Inaba, Kae Okuma, Yuko Nakayama, Kazuaki Shimada, Hitoshi Nakagama, Jun Itami   +20 more
doaj   +1 more source